Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New test may predict lung cancer treatment success

NCT ID NCT04589013

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a combination of 6 markers from tumor tissue could predict how well patients with advanced non-small cell lung cancer respond to first-line treatment with pembrolizumab (immunotherapy) plus chemotherapy. Researchers analyzed tissue samples from 106 patients before treatment and tracked disease progression or death over one year. The goal was to see if this multiparametric test outperforms the standard PD-L1 test alone in predicting outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this test could help doctors identify which lung cancer patients are most likely to benefit from immunotherapy combined with chemotherapy, avoiding ineffective treatments.
What could go wrong
This is a small, completed study that only looked at predicting outcomes, not changing treatment. The test may not be accurate enough for routine use and needs further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

106 people

The number who actually took part.

Started

Nov 2020

Finished

Sep 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients meeting the inclusion criteria will be selected in each of the centers (Lille CHU, Lille Centre Oscar Lambret, Valenciennes Clinique Teissier, Roubaix CH) by the onco-pneumologists and included in the study, after collecting the consent, at the start of treatment with pembrolizumab + chemotherapy in first line.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years at time of diagnosis * Affiliation to a social insurance * Obtaining the patient's non opposition * Patients with non-small cell lung carcinoma, confirmed by anatomopathological, metastatic or locally advanced unresectable, not eligible for local curative treatment * Cellular or tissue FFPE available * Indication of treatment with pembrolizumab + first line chemotherapy in multidisciplinary consultation meeting * No mutation of the EGFR gene, no rearrangement of ALK and ROS, * At least one measurable tumor according to RECIST criteria Exclusion Criteria: * Tissue or cellular FFPE not available * Systemic anti-neoplastic or immunotherapy previously received except neoadjuvant or adjuvant treatment completed 6 months or more

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • CH Victor Provot

    Roubaix, France

  • Clcc Oscar Lambret Lille

    Lille, 59037, France

  • Clinique Teissier

    Valenciennes, France

  • Hop Calmette Chu Lille

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.